Spaedbørnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Spaedbørnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin. / Lauridsen, Mette Høj; Boesgaard, Trine Welløv; Pedersen, Oluf; Hansen, Torben; Hertz, Birgitte.
In: Ugeskrift for læger, Vol. 171, No. 23, 2009, p. 1923-4.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Spaedbørnsdiabetes kan ofte behandles med sulfonylurinstof i stedet for insulin
AU - Lauridsen, Mette Høj
AU - Boesgaard, Trine Welløv
AU - Pedersen, Oluf
AU - Hansen, Torben
AU - Hertz, Birgitte
N1 - Keywords: Child, Preschool; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Female; Glyburide; Humans; Hypoglycemic Agents; Infant; Insulin; Mutation; Potassium Channels, Inwardly Rectifying; Treatment Outcome
PY - 2009
Y1 - 2009
N2 - A two-month-old Danish girl was admitted to the hospital in diabetic ketoacidosis and diagnosed with permanent neonatal diabetes mellitus (PNDM). She received continuous insulin treatment until she was genetically tested at the Steno Diabetes Centre. She carried a KCNJ11 Arg201His mutation, an activating mutation in the KCNJ11-gene which encodes the ATP-sensitive potassium subunit Kir6.2 in the beta cell which is responsible for insulin secretion. As recommended in the literature, she was successfully shifted from insulin therapy to sulfonylurea tablets at the age of three years and nine months. PNDM-patients should be screened for gene mutations regardless of current age. Udgivelsesdato: 2009-Jun-1
AB - A two-month-old Danish girl was admitted to the hospital in diabetic ketoacidosis and diagnosed with permanent neonatal diabetes mellitus (PNDM). She received continuous insulin treatment until she was genetically tested at the Steno Diabetes Centre. She carried a KCNJ11 Arg201His mutation, an activating mutation in the KCNJ11-gene which encodes the ATP-sensitive potassium subunit Kir6.2 in the beta cell which is responsible for insulin secretion. As recommended in the literature, she was successfully shifted from insulin therapy to sulfonylurea tablets at the age of three years and nine months. PNDM-patients should be screened for gene mutations regardless of current age. Udgivelsesdato: 2009-Jun-1
M3 - Tidsskriftartikel
C2 - 19500515
VL - 171
SP - 1923
EP - 1924
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 23
ER -
ID: 13206379